True to its word, Aslan Pharmaceuticals Pte. Ltd. has struck a new in-licensing deal for an asset in the cancer field just weeks after it divested one of its main pipeline projects.
The Singapore-based oncology venture has acquired global development and commercialization rights to an immuno-oncology antibody developed by the p53 Laboratory...







